RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Moleculin Biotech Stock

Moleculin Biotech P/S 2024

Moleculin Biotech P/S

0

Ticker

MBRX

ISIN

US60855D2009

WKN

A2QQM0

As of Aug 1, 2024, Moleculin Biotech's P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.

The Moleculin Biotech P/S history

Moleculin Biotech Aktienanalyse

What does Moleculin Biotech do?

Moleculin Biotech Inc is a biopharmaceutical company based in Houston, Texas, that focuses on the development of innovative cancer therapies. The company was founded in 2015 and has since made significant progress in the research and development of drugs for the treatment of cancer. The company follows an innovative business model consisting of two main divisions: research and development, as well as distribution. Moleculin Biotech focuses on identifying compounds that target specific types and stages of cancer in order to enable personalized cancer treatment. The company currently has several projects in the pipeline, each with the potential to change the way cancer is treated. In the research department, Moleculin Biotech focuses on identifying compounds that target cancer types that have been difficult to treat. The company is dedicated to developing effective drugs that can inhibit cell division in certain types of cancer and stop their growth. The critical goal is to develop medications that selectively attack cancer cells without affecting healthy cells. The distribution department of Moleculin Biotech is responsible for marketing and distributing the developed drugs. The company has a well-established network of distribution partners and agencies that help with the introduction of new products. Moleculin Biotech aims to distribute its products worldwide and continuously expand its patient base. One of Moleculin Biotech's key products is the compound WP1122. This molecule is a prodrug capable of selectively accumulating and acting in cancer cells. As a result, it can be used in combination with other cancer therapies to increase treatment efficacy. The company has already demonstrated the potential of WP1122 in clinical trials and is currently working on its market launch. Another significant product of Moleculin Biotech is Annamycin. This is a chemotherapeutic specifically developed for the treatment of leukemia. The medication has already been tested in clinical trials and proven to be effective. Annamycin has the potential to dramatically change and improve the treatment of leukemia. In addition to these two products, Moleculin Biotech also has MSP-2017 in its portfolio. This anti-tumor drug specifically targets pancreatic cancer and has the potential to increase the survival rate of patients in advanced stages of the disease. MSP-2017 is currently still in the development phase and is expected to enter the market in the coming years. Overall, Moleculin Biotech is a promising company focusing on the development of innovative cancer therapies. The company has the potential to fundamentally change cancer treatment and save the lives of millions of people worldwide. The company is committed to intensifying its research and development activities and continuously expanding its product pipeline. Moleculin Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Moleculin Biotech's P/S Ratio

Moleculin Biotech's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Moleculin Biotech's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Moleculin Biotech's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Moleculin Biotech’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Moleculin Biotech stock

What is the price-to-earnings ratio of Moleculin Biotech?

The price-earnings ratio of Moleculin Biotech is currently 0.

How has the price-earnings ratio of Moleculin Biotech changed compared to last year?

The price-to-earnings ratio of Moleculin Biotech has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Moleculin Biotech high compared to other companies?

Yes, the price-to-earnings ratio of Moleculin Biotech is high compared to other companies.

How does an increase in the price-earnings ratio of Moleculin Biotech affect the company?

An increase in the price-earnings ratio of Moleculin Biotech would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Moleculin Biotech affect the company?

A decrease in the price-earnings ratio of Moleculin Biotech would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Moleculin Biotech?

Some factors that influence the price-earnings ratio of Moleculin Biotech are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Moleculin Biotech pay?

Over the past 12 months, Moleculin Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Moleculin Biotech is expected to pay a dividend of 0 USD.

What is the dividend yield of Moleculin Biotech?

The current dividend yield of Moleculin Biotech is .

When does Moleculin Biotech pay dividends?

Moleculin Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Moleculin Biotech?

Moleculin Biotech paid dividends every year for the past 0 years.

What is the dividend of Moleculin Biotech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Moleculin Biotech located?

Moleculin Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Moleculin Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Moleculin Biotech from 8/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/1/2024.

When did Moleculin Biotech pay the last dividend?

The last dividend was paid out on 8/1/2024.

What was the dividend of Moleculin Biotech in the year 2023?

In the year 2023, Moleculin Biotech distributed 0 USD as dividends.

In which currency does Moleculin Biotech pay out the dividend?

The dividends of Moleculin Biotech are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Moleculin Biotech

Our stock analysis for Moleculin Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Moleculin Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.